---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-08-18T09:37:41.500768'
end_time: '2026-08-18T09:47:34.261646'
duration_seconds: 592.77
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Loeys-Dietz Syndrome 6
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 25
reference_validation:
  total_references: 7
  verified: 7
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 7
  on_topic: 3
  validator_version: 0.2.1
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: Loeys-Dietz_Syndrome_6-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Loeys-Dietz Syndrome 6
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Loeys-Dietz Syndrome 6** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Loeys-Dietz Syndrome 6
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Loeys-Dietz Syndrome 6** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


# Loeys–Dietz Syndrome 6 (SMAD2-Related) — Disease Characteristics Research Report

**Scope and evidence grading.** Loeys–Dietz syndrome type 6 (LDS6) is exceptionally rare, and “LDS6” is not used consistently. This report therefore distinguishes: **[Direct LDS6]** evidence involving germline **SMAD2** variants; **[Pan-LDS]** evidence from genetically heterogeneous Loeys–Dietz syndrome; and **[HTAD/model]** evidence extrapolated from hereditary thoracic aortic disease or other TGF-β-pathway LDS models. Quantitative phenotype frequencies, penetrance, treatment response, and prognosis specific to LDS6 are largely unavailable.

A compact knowledge-base summary follows.

| Domain | Best-supported LDS6-specific statement | Suggested ontology/identifier | Evidence scope/caveat |
|---|---|---|---|
| Disease identity | Loeys-Dietz syndrome type 6 is the *rarely used* designation for monoallelic **SMAD2**-related syndromic aortopathy within the broader Loeys-Dietz syndrome spectrum; some authors note the subtype label is inconsistently used. (asta2023geneticbasisnew pages 3-5, ebeling2024differentiationpurificationand pages 9-11, OpenTargets Search: Loeys-Dietz syndrome-SMAD2) | **SMAD2** (HGNC approved symbol); broader disease **MONDO:0018954** Loeys-Dietz syndrome; MeSH **D055947** | Direct for SMAD2 as LDS6; broader MONDO/MeSH refer to pan-LDS, not subtype-specific LDS6. |
| Core molecular cause | LDS6 is caused by heterozygous pathogenic variants in **SMAD2**, a receptor-regulated SMAD in canonical TGF-β signaling; Open Targets links SMAD2 to Loeys-Dietz syndrome with supportive genetic literature and monoallelic inheritance evidence. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2, asta2023geneticbasisnew pages 3-5) | NCBI/Ensembl target: **SMAD2 / ENSG00000175387**; pathway **TGF-β signaling** | Direct association supported; variant-level LDS6 details remain sparse in retrieved sources. |
| Inheritance | Inheritance is **autosomal dominant / monoallelic**; across LDS, ~25% have an affected parent and many cases are de novo, with familial cases often milder. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2, ebeling2024differentiationpurificationand pages 9-11, zaza2022cleftpalateand pages 2-5) | HPO inheritance term analogous to **Autosomal dominant inheritance**; MONDO broader LDS | Monoallelic inheritance supported for SMAD2/LDS association; de novo/familial proportions are from pan-LDS, not LDS6-only cohorts. |
| Hallmark vascular phenotype | The best-supported disease-defining manifestation for LDS6 is **thoracic aortic aneurysm/dissection predisposition** within a syndromic aortopathy phenotype. SMAD2 mutations were linked to a new LDS form after study of families with aneurysm/dissection and increased aortic-wall SMAD2 expression. (asta2023geneticbasisnew pages 3-5) | HPO: **Aortic root dilatation**, **Thoracic aortic aneurysm**, **Aortic dissection**, **Arterial tortuosity** | Direct but limited foundational LDS6 evidence; frequencies/age-specific penetrance not available in retrieved subtype-specific data. |
| Extra-aortic syndromic features | LDS6 is expected to overlap with classic LDS features such as **hypertelorism**, **bifid uvula/cleft palate**, skeletal/connective-tissue findings, and mitral valve disease. (asta2023geneticbasisnew pages 3-5, zaza2022cleftpalateand pages 2-5) | HPO: **Hypertelorism**, **Bifid uvula**, **Cleft palate**, **Arachnodactyly**, **Joint hypermobility/stiffness**, **Mitral valve disease** | Mostly extrapolated from pan-LDS and TGFB3/TGFBR2 examples; LDS6-specific frequencies unavailable. |
| Pathway mechanism | SMAD2 acts downstream of TGFBR1/2; after receptor activation, phosphorylated SMAD2/3 complexes regulate transcription. LDS/related aortopathy literature supports paradoxical tissue-level **increased pSMAD2/3** despite impaired signaling in some cell contexts. (liu2025anoveltgfbr2 pages 7-8, asta2023geneticbasisnew pages 3-5, macfarlane2019lineagespecificeventsunderlie pages 2-5, NCT05472519 chunk 1) | GO: **TGF-beta receptor signaling pathway**, **SMAD protein signal transduction**, **regulation of transcription by RNA polymerase II** | Mostly pathway-level and non-LDS6-specific mechanistic inference; direct SMAD2-LDS6 functional assays were not retrieved. |
| Cellular context | Aortic disease mechanisms center on **vascular smooth muscle cells (VSMCs)** and likely endothelial/fibroblast contributions; lineage-specific LDS mouse work shows defective TGF-β/Smad induction in a susceptible VSMC lineage can localize root aneurysm. (macfarlane2019lineagespecificeventsunderlie pages 2-5, ganizada2024unveilingcellularand pages 14-15) | CL: **vascular smooth muscle cell**, **endothelial cell**, **fibroblast** | Strong for LDS pathway biology, but model used Tgfbr1-LDS rather than SMAD2-LDS6. |
| Anatomy affected | Primary site is the **aortic root/ascending thoracic aorta**; broader LDS may also involve aortic arch, descending aorta, branch vessels, and craniofacial/connective tissues. (macfarlane2019lineagespecificeventsunderlie pages 2-5, spaziani2024hereditarythoracicaortic pages 7-9, zaza2022cleftpalateand pages 2-5) | UBERON: **aortic root**, **ascending aorta**, **aortic arch**, **descending aorta**, **palate**, **arterial vasculature** | LDS6-specific anatomic distribution unresolved; broader LDS/HTAD imaging evidence used. |
| Diagnostics | Recommended workup is syndrome recognition plus **genetic testing** and **multimodality aortic imaging**. In HTAD/LDS, testing often uses multigene panels/WES, with cascade testing of first-degree relatives when positive; echo is first-line, CT/CMR define full aortic extent. (asta2023geneticbasisnew pages 5-8, spaziani2024hereditarythoracicaortic pages 7-9, zaza2022cleftpalateand pages 2-5) | Diagnostic resources: multigene **HTAD/LDS panel**, **WES**; imaging **TTE**, **CT/CCTA**, **CMR/MRA** | This is current practice extrapolated from pan-LDS/HTAD; no LDS6-specific diagnostic criteria were retrieved. |
| Differential diagnosis | Important differentials include **Marfan syndrome**, other **Loeys-Dietz subtypes**, **vascular Ehlers-Danlos syndrome**, and non-syndromic/familial HTAD. (asta2023geneticbasisnew pages 5-8, ebeling2024differentiationpurificationand pages 9-11, NCT01322165 chunk 1) | MONDO/HPO differential set; genes commonly contrasted: **FBN1, TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, COL3A1** | Extrapolated from broader inherited aortopathy literature. |
| Management | No randomized LDS-specific medical therapy trials were identified; current guidance is **blood-pressure control**, avoidance of stimulants/vasoconstrictors, exercise restriction, and multidisciplinary surveillance. Use of **ARBs (especially losartan)**, **beta-blockers**, or **ACE inhibitors** is commonly extrapolated from Marfan/LDS management. (spaziani2024hereditarythoracicaortic pages 7-9, spaziani2024hereditarythoracicaortic pages 9-10, zaza2022cleftpalateand pages 2-5) | NCIT-style interventions: **Losartan**, **Angiotensin receptor blocker**, **Beta-adrenergic blocker**, **ACE inhibitor**, **Aortic surgery** | Pan-LDS/HTAD extrapolation; no LDS6-specific efficacy data retrieved. |
| Surgical intervention | Elective aortic surgery is used when anatomy or growth rate indicates high risk; retrieved LDS-oriented material notes intervention for critical aortic size/rapid growth, but subtype-specific diameter thresholds for LDS6 were not retrieved. (ebeling2024differentiationpurificationand pages 9-11, spaziani2024hereditarythoracicaortic pages 9-10) | NCIT: **Aortic root replacement**, **Vascular surgical procedure** | Threshold details here are not LDS6-specific and should not be overinterpreted. |
| Prevention/counseling | Secondary/tertiary prevention relies on **early diagnosis**, **cascade family screening**, serial imaging, and counseling on pregnancy/exertion risk. Prenatal diagnosis is possible when the familial pathogenic variant is known. (asta2023geneticbasisnew pages 5-8, zaza2022cleftpalateand pages 2-5) | Counseling concepts: **cascade screening**, **prenatal testing**, **genetic counseling** | Mostly pan-LDS evidence; LDS6-specific pregnancy outcome data not retrieved. |
| Epidemiology | LDS overall is rare; retrieved sources estimate prevalence as **below 1 in 100,000** or **1/25,000-1/100,000**. One recent review table estimated **LDS6/SMAD2 accounts for ~1-5% of LDS**. (ebeling2024differentiationpurificationand pages 9-11, NCT05472519 chunk 1) | Broader disease epidemiology for **Loeys-Dietz syndrome** | Estimates are broad and not population-based for LDS6 specifically. |
| Models and translational resources | Relevant resources include **GenTAC** registry infrastructure for genetically triggered thoracic aortopathy and a completed **I-LoDiS** immunopathology study in LDS; patient-specific iPSC/endothelial disease-modeling work exists for LDS broadly. (NCT01322165 chunk 1, NCT05472519 chunk 1, ebeling2024differentiationpurificationand pages 9-11) | Clinical trials/registries: **NCT01322165** GenTAC; **NCT05472519** I-LoDiS | Valuable for LDS research, but not specific to SMAD2/LDS6 in the retrieved records. |
| Major evidence gaps | Major LDS6 gaps include: lack of subtype-specific prevalence, penetrance, phenotype frequencies, validated biomarkers, surgical thresholds, pregnancy outcomes, treatment response data, and retrieved direct SMAD2 functional variant studies. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2, ebeling2024differentiationpurificationand pages 9-11) | Evidence-gap annotation | Important to distinguish direct LDS6 evidence from broader LDS/HTAD extrapolation in any knowledge base entry. |


*Table: This table summarizes the best-supported findings for SMAD2-related Loeys-Dietz syndrome 6, while clearly separating subtype-specific evidence from broader Loeys-Dietz syndrome and hereditary thoracic aortic disease extrapolations. It is useful as a compact knowledge-base scaffold for curation and evidence-gap tracking.*

## 1. Disease information

### Definition

**[Direct LDS6]** LDS6 is a Mendelian, autosomal-dominant syndromic aortopathy caused by a heterozygous pathogenic variant in **SMAD2**, which encodes a receptor-regulated intracellular effector of TGF-β signaling. Its defining clinical risk is progressive arterial disease—particularly thoracic/aortic-root aneurysm, dissection, or rupture—with variable craniofacial, skeletal, cutaneous, and cardiac-valvular connective-tissue manifestations. A 2023 review states that “type 6 [is] determined by the SMAD2 mutation” and attributes the initial association to families with aneurysm/dissection and abnormal aortic-wall SMAD2 expression. (asta2023geneticbasisnew pages 3-5)

Because SMAD2-related disease has been reported only rarely, some authors use **“SMAD2-related syndromic thoracic aortic aneurysm and dissection”** rather than LDS6. A 2024 dissertation reviewing LDS disease models explicitly notes that “LDS type 6 is not consistently used in literature.” (ebeling2024differentiationpurificationand pages 9-11)

### Identifiers and synonyms

- **MONDO:** No subtype-specific MONDO identifier was verified in the retrieved evidence. The broader Loeys–Dietz syndrome term is **MONDO:0018954**.
- **MeSH:** **D055947**, Loeys-Dietz Syndrome, broader disease term. (NCT05472519 chunk 1)
- **OMIM:** Broader LDS entries cited by the retrieved literature include **609192** and **610168**, historically corresponding to receptor-defined LDS forms rather than a confirmed subtype-specific LDS6 record. These should not be assigned to LDS6 without independent OMIM verification. (ebeling2024differentiationpurificationand pages 9-11)
- **ICD-10:** No dedicated LDS6 code. LDS is commonly grouped under **Q87.4** in the retrieved source; local coding may instead use congenital malformation/connective-tissue or aortic-disease codes. (ebeling2024differentiationpurificationand pages 9-11)
- **ICD-11:** No verified subtype-specific code retrieved.
- **Synonyms:** *Loeys-Dietz syndrome type 6*, *LDS type 6*, *LDS6*, *SMAD2-related Loeys-Dietz syndrome*, *SMAD2-related syndromic aortopathy*, *SMAD2-related hereditary thoracic aortic disease*.
- **Gene:** **SMAD2**, Ensembl **ENSG00000175387**. Open Targets reports five genetic evidence items and an LDS–SMAD2 association score of approximately 0.76. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2)

### Data provenance

The entry is based primarily on **aggregated disease resources, published families/case series, reviews, and registries**, not individual-level EHR data. GenTAC collected longitudinal clinical data and biospecimens from 3,706 people with genetically triggered aortic conditions, including LDS, but the retrieved record does not provide an LDS6 subgroup. (NCT01322165 chunk 1)

## 2. Etiology

### Causal factor and genetic risk

**[Direct LDS6]** The primary cause is a **germline heterozygous pathogenic/likely pathogenic SMAD2 variant**. Open Targets/Genomics England evidence supports monoallelic inheritance and includes stop-gained and splice-acceptor variant records, although complete HGVS descriptions were not present in the retrieved material. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2)

Reported pathogenic classes include **missense, nonsense/truncating, and splice-disrupting variants**. The 2023 review particularly associates missense and nonsense SMAD2 variants with LDS6. Exact domain-specific genotype–phenotype relationships remain insufficiently established. (asta2023geneticbasisnew pages 3-5)

The strongest risk factors are therefore:

1. A pathogenic germline **SMAD2** allele.
2. An affected first-degree relative or family history of thoracic aortic aneurysm/dissection or sudden unexplained death.
3. Established aneurysm, rapid arterial growth, hypertension, and pregnancy-related hemodynamic stress—clinically important modifiers extrapolated from pan-LDS/HTAD.

### Environmental and lifestyle risk factors

No environmental exposure causes LDS6. **Hypertension**, stimulant or vasoconstrictor exposure, smoking, and high-static/straining exercise may add mechanical stress to a genetically vulnerable arterial wall; however, no LDS6-specific effect sizes are available. Current HTAD management emphasizes blood-pressure control, avoidance of stimulants/vasoconstrictors, and exercise restriction. (spaziani2024hereditarythoracicaortic pages 7-9)

No infectious trigger is recognized. LDS6 is **not contagious or zoonotic**.

### Protective factors

No genetically protective SMAD2 allele or validated modifier gene has been established. Clinically protective measures are secondary/tertiary rather than etiologic: early molecular diagnosis, serial whole-arterial imaging, strict blood-pressure control, avoidance of high-strain activity, and appropriately timed prophylactic surgery. Evidence for beta-blockers or angiotensin-receptor blockers in LDS is indirect; no randomized LDS trial has shown reduced dissection risk. (spaziani2024hereditarythoracicaortic pages 9-10)

### Gene–environment interaction

The working model is that SMAD2 dysfunction lowers arterial resilience while **blood pressure, pulse-wave stress, pregnancy, and intense isometric exertion** increase wall loading. This interaction may accelerate dilation or precipitate dissection, but it has not been quantified for LDS6.

## 3. Phenotypes

The following are reasonable curation targets. Unless stated otherwise, frequencies and age distributions are **unknown for LDS6**.

### Vascular and cardiac

- **Aortic-root/ascending thoracic aortic dilatation or aneurysm** — clinical sign/imaging abnormality; congenital through adult onset; progressive and potentially severe. Suggested HPO: **Aortic root dilatation**, **Thoracic aortic aneurysm**.
- **Aortic dissection/rupture** — acute vascular complication superimposed on lifelong susceptibility; life-threatening. HPO: **Aortic dissection**, **Aortic rupture**.
- **Aneurysms/dissections outside the proximal aorta** and **arterial tortuosity** — expected within the broader LDS phenotype but LDS6-specific distribution is unresolved. HPO: **Arterial tortuosity**, **Generalized arterial tortuosity**, **Arterial aneurysm**.
- **Mitral-valve disease** and possibly aortic regurgitation — HPO: **Mitral valve prolapse**, **Mitral regurgitation**, **Aortic regurgitation**. The literature associates SMAD2-mutant families primarily with aneurysm/dissection, while valvular manifestations are better documented across LDS. (asta2023geneticbasisnew pages 3-5)

A pan-LDS neonatal example illustrates that disease can be evident at birth: a TGFBR2-positive newborn had a 16–17-mm aortic root with z-scores of +7.46 to +8.65 and tortuous major branches. This is not LDS6 evidence but demonstrates the possible congenital end of the LDS spectrum. (zaza2022cleftpalateand pages 2-5)

### Craniofacial, skeletal, and cutaneous

Possible features include:

- **Hypertelorism** — HPO: *Hypertelorism*.
- **Bifid uvula or cleft palate** — HPO: *Bifid uvula*, *Cleft palate*.
- **Arachnodactyly**, joint hypermobility or contractures, scoliosis, pectus deformity, and clubfoot — corresponding HPO terms should be assigned when observed.
- Translucent/soft skin, easy bruising, or abnormal scarring — pan-LDS features; use phenotype-specific HPO terms rather than assuming presence.

These features are diagnostically supportive but neither necessary nor sufficient for LDS6. Their frequency in SMAD2-positive individuals is unknown. (asta2023geneticbasisnew pages 3-5, zaza2022cleftpalateand pages 2-5)

### Allergic, gastrointestinal, neurologic, and behavioral features

Asthma, eczema, food allergy, elevated IgE/eosinophilia, eosinophilic gastrointestinal disease, and inflammatory bowel disease occur in **pan-LDS**, especially receptor-associated LDS, but have not been established as defining LDS6 features. The completed I-LoDiS study enrolled only TGFBR1/TGFBR2-positive participants, so its findings should not be directly transferred to SMAD2-related disease. (NCT05472519 chunk 1)

No characteristic behavioral or psychiatric phenotype, laboratory abnormality, or neurodevelopmental syndrome is established for LDS6.

### Quality of life

No LDS6-specific EQ-5D, SF-36, PROMIS, or disease-specific patient-reported outcome data were found. Likely burdens include anxiety about dissection, repeated imaging, exercise and pregnancy restrictions, chronic musculoskeletal symptoms, and recovery from major vascular surgery. These should be recorded as anticipated consequences, not measured LDS6 statistics.

## 4. Genetic and molecular information

### Gene and protein

- **Gene:** **SMAD2**, HGNC-approved symbol; chromosome **18q21.1**.
- **Protein:** Mothers against decapentaplegic homolog 2/SMAD family member 2, a receptor-regulated SMAD.
- **Function:** Following TGFBR1-mediated phosphorylation, SMAD2 associates with SMAD3/SMAD4-containing complexes, enters the nucleus, and regulates transcription. (liu2025anoveltgfbr2 pages 7-8)

### Variant interpretation

Testing laboratories should classify variants using ACMG/AMP criteria. Evidence expected for pathogenicity includes rarity/absence in population databases, segregation or de novo occurrence, predicted loss of function where applicable, location in a critical functional domain, and validated functional impairment. A **VUS must not by itself establish LDS6 or direct prophylactic surgery**.

Open Targets summarizes stop-gained and splice-acceptor disease records and monoallelic inheritance evidence, but the retrieved sources do not provide a complete curated list of SMAD2 HGVS variants or their gnomAD frequencies. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2)

- **Origin:** Germline; somatic SMAD2 variants in cancer are not the cause of constitutional LDS6.
- **Mechanistic class:** Likely loss of normal canonical signaling, dominant-negative effects for some alleles, or haploinsufficiency for truncating/splice variants. Variant-specific mechanisms require functional confirmation.
- **Structural variants:** Large deletions/rearrangements disrupting SMAD2 are biologically plausible; no recurrent LDS6 chromosomal abnormality was established in the retrieved evidence.
- **Modifier genes/epigenetics:** No validated LDS6 modifier gene, methylation signature, or clinical epigenetic biomarker was found.

## 5. Environmental information

No toxin, radiation exposure, occupational agent, diet, infection, alcohol use, or smoking exposure is known to initiate LDS6. Smoking and uncontrolled hypertension should nevertheless be minimized because of general adverse vascular effects. Contact/collision sports, heavy weightlifting, intense isometric exercise, and activities requiring Valsalva maneuvers are generally restricted in heritable aortopathy; recommendations should be individualized to arterial dimensions, prior surgery, and blood-pressure response. (spaziani2024hereditarythoracicaortic pages 7-9)

## 6. Mechanism and pathophysiology

### Causal chain

1. **Upstream trigger:** constitutional heterozygous SMAD2 pathogenic variant.
2. **Primary biochemical defect:** altered transmission of signals from activated TGFBR1/2 through phosphorylated SMAD2/3 complexes to nuclear transcriptional programs.
3. **Cellular dysfunction:** disturbed vascular smooth-muscle-cell differentiation/contractile homeostasis, stress responses, and communication with extracellular matrix, endothelial cells, fibroblasts, and immune cells.
4. **Tissue remodeling:** reduced elastic integrity, diffuse medial degeneration, elastic-fiber fragmentation, collagen and amorphous extracellular-matrix accumulation, and maladaptive matrix turnover.
5. **Biomechanical consequence:** progressive arterial-wall weakening and altered compliance.
6. **Clinical manifestations:** aortic-root/arterial dilatation → aneurysm → dissection or rupture; associated valve, craniofacial, skeletal, and cutaneous abnormalities reflect broader developmental TGF-β dysregulation. (asta2023geneticbasisnew pages 3-5)

### The signaling paradox

TGF-β-pathway mutations may reduce ligand-induced signaling cell-autonomously yet coexist with **increased tissue pSMAD2/3** at sites of aneurysm. In a Tgfbr1 LDS mouse, second-heart-field-derived aortic-root VSMCs had defective ligand-induced pSmad2/3, while diseased aortic-root tissue later showed localized increases in pSmad2/3 and TGF-β1/TGF-β3 that tracked with dilation. This supports secondary compensatory or non-cell-autonomous signaling rather than a simple global “gain” or “loss” model. (macfarlane2019lineagespecificeventsunderlie pages 2-5)

### Cells, tissues, and ontology suggestions

- **CL:** vascular smooth muscle cell; endothelial cell; fibroblast; macrophage; T lymphocyte.
- **GO Biological Process:** *transforming growth factor beta receptor signaling pathway*; *SMAD protein signal transduction*; *regulation of transcription by RNA polymerase II*; *extracellular matrix organization*; *elastic fiber assembly*; *smooth muscle cell differentiation*; *response to mechanical stimulus*.
- **GO Cellular Component:** cytosol, nucleus, SMAD protein complex, receptor complex, extracellular matrix.

### Molecular profiling and advanced technologies

No LDS6-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, or lipidomic signature was found. Broader ascending-aortic studies report candidate circulating markers such as MMP-1/2/3/9, IL-6, GDF-15, miR-574-5p, C18-ceramide, aggrecan, and alpha-2-HS-glycoprotein, but none is validated for diagnosing or forecasting LDS6. (ganizada2024unveilingcellularand pages 14-15)

Patient-specific iPSC-derived endothelial cells are being developed for LDS modeling, offering a platform for genotype-specific endothelial phenotyping and drug testing. The retrieved 2024 work is methodological and does not establish a validated LDS6 biomarker or treatment. (ebeling2024differentiationpurificationand pages 9-11)

## 7. Anatomical structures affected

### Organ/system level

- **Primary:** aortic root and ascending thoracic aorta; potentially the entire aorta and medium/large arterial tree.
- **Secondary:** heart valves; craniofacial skeleton and palate; axial/appendicular skeleton; skin and connective tissues.
- **Systems:** cardiovascular, musculoskeletal, craniofacial, integumentary; possible allergic/gastrointestinal involvement based on pan-LDS.

### UBERON suggestions

*Aortic root*, *ascending aorta*, *aortic arch*, *descending thoracic aorta*, *abdominal aorta*, *arterial wall*, *tunica media of artery*, *heart valve*, *palate*, *skin*, *vertebral column*.

Aortic medial VSMCs are the principal implicated cell population. The relevant subcellular route spans plasma-membrane TGF-β receptor complexes, cytosolic SMAD phosphorylation/complex assembly, and nuclear transcription. No characteristic lateralization exists; vascular and skeletal findings may be bilateral or asymmetric depending on manifestation.

## 8. Temporal development

LDS6 is a **congenital genetic condition with lifelong risk**, even when no abnormality is visible at birth. Clinical onset ranges from prenatal/neonatal aortic dilation to childhood or adult discovery of aneurysm/dissection. Progression is chronic but highly variable; acute dissection is a catastrophic event superimposed on this chronic substrate.

No validated LDS6 staging system exists. A practical clinical course is:

1. Genotype-positive/no detectable arterial disease.
2. Stable or enlarging arterial tortuosity/dilatation.
3. Clinically significant aneurysm or rapid growth.
4. Dissection/rupture or prophylactic/emergency repair.
5. Lifelong post-repair surveillance for residual native-vessel disease.

There is no spontaneous remission. Critical intervention windows are **before dissection**, during family cascade screening, after detection of rapid growth, and before/during pregnancy. Pan-LDS literature reports nonpenetrance and mosaicism, underscoring that a normal early examination does not eliminate later risk. (zaza2022cleftpalateand pages 2-5)

## 9. Inheritance and population

### Inheritance

- **Pattern:** autosomal dominant/monoallelic.
- **Recurrence:** an affected heterozygous individual has a **50% probability** of transmitting the variant in each pregnancy.
- **De novo disease:** Across LDS, approximately 25% have an affected parent and the remainder are described as de novo; another retrieved review states roughly 75% are de novo. These are pan-LDS estimates, not LDS6-specific rates. (ebeling2024differentiationpurificationand pages 9-11, zaza2022cleftpalateand pages 2-5)
- **Penetrance:** incompletely defined and probably age dependent; nonpenetrance has been reported across LDS.
- **Expressivity:** markedly variable.
- **Anticipation:** not established.
- **Germline mosaicism:** theoretically relevant to apparently de novo recurrence, but no LDS6 rate is available.
- **Founder effects, consanguinity, carrier frequency:** none established; consanguinity is not expected to drive an autosomal-dominant disorder.

### Epidemiology

LDS overall has been estimated at **<1 in 100,000** or approximately **1 in 25,000–100,000**, but robust population-based incidence and prevalence are lacking. A recent summary estimated SMAD2/LDS6 at **1–5% of LDS**, which is an approximate relative fraction rather than a population prevalence. (ebeling2024differentiationpurificationand pages 9-11, NCT05472519 chunk 1)

No reproducible ethnic, geographic, sex, or founder enrichment has been established for LDS6. All sexes can be affected. Pregnancy creates an additional vascular/uterine risk for affected women, while the germline transmission probability is sex independent.

## 10. Diagnostics

### Clinical evaluation

Diagnosis begins with personal/family history, three-generation pedigree, physical examination, and cardiovascular imaging. Suspicion should increase with early-onset aortic aneurysm/dissection, arterial tortuosity, bifid uvula/cleft palate, hypertelorism, marfanoid skeletal features, or a family history of sudden aortic death.

### Imaging

- **Transthoracic echocardiography:** first-line measurement of aortic root/ascending aorta and valve function.
- **CT angiography:** rapid, high-resolution evaluation of the entire aorta and branch vessels; useful for acute disease and surgical planning but entails radiation/contrast.
- **CMR/MRA:** preferred for repeated longitudinal imaging in many children and young adults because it avoids ionizing radiation and can characterize the full aorta and hemodynamics. (asta2023geneticbasisnew pages 5-8, spaziani2024hereditarythoracicaortic pages 7-9)

Whole-arterial baseline imaging is important because echocardiography does not visualize every vulnerable segment. Imaging intervals should be individualized by genotype, age, dimensions, growth, family history, and prior surgery.

### Genetic testing

1. Use a comprehensive **heritable thoracic aortic disease panel** including at least **SMAD2, TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, FBN1, COL3A1, ACTA2, MYH11, MYLK, LOX, PRKG1**, and other validated HTAD genes.
2. Ensure sequencing plus deletion/duplication analysis.
3. Use exome or genome sequencing when panel testing is negative, phenotype is atypical, or structural/noncoding disease is suspected.
4. Confirm candidate variants and perform segregation/de novo analysis where possible.
5. Offer targeted cascade testing to relatives when a pathogenic familial variant is identified. If testing is negative or yields only a VUS, at-risk relatives may still require imaging based on family history. (asta2023geneticbasisnew pages 5-8)

CMA, karyotype, or FISH is not first-line for isolated suspected LDS6 but may be appropriate for syndromic developmental abnormalities or suspected larger rearrangements. Mitochondrial and repeat-expansion testing are not indicated. RNA sequencing may help resolve splice variants but is not standard primary diagnosis.

### Differential diagnosis

- Other LDS subtypes: **TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3**.
- Marfan syndrome: **FBN1**, commonly ectopia lentis and classic Ghent phenotype.
- Vascular Ehlers–Danlos syndrome: **COL3A1**, marked tissue/arterial fragility.
- Shprintzen–Goldberg syndrome: **SKI**, craniosynostosis and developmental phenotype.
- Arterial tortuosity syndrome: **SLC2A10**, autosomal recessive.
- Familial nonsyndromic HTAD and bicuspid-aortic-valve aortopathy.

No single biochemical blood test or histopathologic criterion diagnoses LDS6. Candidate circulating ATAA biomarkers remain investigational. (ganizada2024unveilingcellularand pages 14-15)

## 11. Outcome and prognosis

The principal morbidity and mortality arise from **aortic or arterial dissection/rupture**, emergency surgery, stroke/malperfusion, valve disease, and repeated vascular interventions. Untreated acute type-A dissection is highly lethal; a general aortic-disease source cited mortality of 54% untreated versus 12–26% after surgery, but these are not LDS6-specific figures. (ebeling2024differentiationpurificationand pages 9-11)

No LDS6-specific life expectancy, 5-/10-year survival, mortality rate, or validated prognostic model was found. Prognosis is expected to improve substantially with early diagnosis, blood-pressure control, surveillance, and prophylactic repair. Adverse prognostic factors likely include early or diffuse arterial disease, rapid enlargement, family history of dissection at small diameter, uncontrolled hypertension, pregnancy, and residual native aorta after repair. These are clinically plausible pan-HTAD factors rather than quantified LDS6 predictors.

No validated prognostic biomarker exists. Aortic diameter and growth remain central but imperfect risk measures.

## 12. Treatment

### Medical therapy

No medication corrects the germline defect, and **no randomized trial has demonstrated reduced aortic growth or dissection specifically in LDS or LDS6**. Current practice extrapolates from Marfan syndrome and mechanistic models:

- **Beta-blocker**—reduces heart rate, blood pressure, and pulsatile wall stress.
- **Angiotensin II receptor blocker**, commonly **losartan**—reduces blood pressure and may influence maladaptive TGF-β/ERK signaling.
- **ACE inhibitor**—alternative/additional blood-pressure control.

A 2024 HTAD review concludes that ARBs, beta-blockers, or ACE inhibitors are reasonable to lessen hemodynamic stress and that prophylactic ARB use may be considered in genotype-positive LDS with relevant family/variant history, while explicitly acknowledging the absence of LDS efficacy studies. (spaziani2024hereditarythoracicaortic pages 9-10)

Suggested NCIT-style intervention concepts: *Beta Adrenergic Blocker*, *Angiotensin II Receptor Antagonist*, *Losartan*, *Angiotensin-Converting Enzyme Inhibitor*, *Antihypertensive Therapy*.

Doxycycline, statins, MMP inhibition, direct TGF-β inhibition, and other pathway-directed agents remain experimental for inherited aortopathy and should not be represented as established LDS6 treatment. Calcium-channel blockers should be used cautiously in syndromic aortopathy. (spaziani2024hereditarythoracicaortic pages 9-10)

### Surgery

Elective **valve-sparing aortic-root replacement** or composite graft replacement is the definitive preventive intervention when risk becomes unacceptable. Decisions should be genotype- and patient-specific, incorporating absolute diameter, body size/z-score, growth rate, family history, valve function, pregnancy plans, and surgical expertise. The retrieved sources did not provide a validated SMAD2-specific threshold; therefore, generic 40–50-mm statements must not be treated as an LDS6 rule. (ebeling2024differentiationpurificationand pages 9-11)

Suggested NCIT concepts: *Aortic Root Replacement*, *Valve-Sparing Aortic Root Replacement*, *Aortic Aneurysm Repair*, *Vascular Surgery*.

### Supportive care

Multidisciplinary care may include cardiology/aortopathy, cardiovascular surgery, medical genetics, maternal–fetal medicine, orthopedics, craniofacial/ENT, allergy/gastroenterology, physiotherapy, occupational therapy, pain management, and psychological support.

### Advanced and experimental therapeutics

No approved gene therapy, CRISPR treatment, cell therapy, RNA therapy, or LDS6-specific targeted biologic was found. Editing a dominant SMAD2 allele would require allele-specific safety, delivery to the arterial wall, and careful avoidance of disrupting essential TGF-β functions.

### Trials and real-world implementations

- **GenTAC, NCT01322165:** completed prospective registry; 3,706 participants across genetic aortopathies; longitudinal outcomes and biospecimens. (NCT01322165 chunk 1)
- **I-LoDiS, NCT05472519:** completed 2023, 60 participants; investigated immune populations and pSMAD2/3, but eligibility was restricted to TGFBR1/TGFBR2-positive LDS and therefore does not directly study LDS6. (NCT05472519 chunk 1)
- No LDS6-specific therapeutic interventional trial was identified.

## 13. Prevention

### Primary prevention

The inherited variant cannot presently be prevented after conception. Reproductive options after identification of a familial pathogenic variant include genetic counseling, preimplantation genetic testing, chorionic-villus sampling, or amniocentesis. Prenatal ultrasound has low sensitivity for many LDS manifestations, though severe prenatal aortic dilation may occasionally be detected. (zaza2022cleftpalateand pages 2-5)

### Secondary prevention

- Cascade genetic testing and baseline cardiovascular imaging of first-degree relatives.
- Early whole-aorta/arterial imaging in genotype-positive individuals.
- Regular blood-pressure assessment and treatment.
- Pregnancy risk assessment before conception.

### Tertiary prevention

- Serial multimodality imaging.
- Medical reduction of hemodynamic stress.
- Avoidance of smoking, stimulants/vasoconstrictors, collision sports, heavy isometric exertion, and Valsalva-heavy lifting.
- Timely prophylactic vascular surgery.
- Lifelong surveillance after repair because unrepaired arterial segments remain at risk. (spaziani2024hereditarythoracicaortic pages 7-9, spaziani2024hereditarythoracicaortic pages 9-10)

No immunization, infectious prophylaxis, newborn biochemical screening, or population-wide screening program is applicable. Targeted familial screening is the appropriate public-health strategy.

## 14. Other species and natural disease

No well-established naturally occurring veterinary LDS6 caused by an orthologous **SMAD2** variant was identified. SMAD2 is evolutionarily conserved across vertebrates, consistent with conserved TGF-β developmental and vascular functions, but conservation alone does not demonstrate natural disease.

- **Human:** *Homo sapiens*, NCBI Taxonomy **9606**.
- Common experimental comparison species include *Mus musculus* (**10090**) and *Danio rerio* (**7955**).
- No breed-specific VBO annotation, veterinary prevalence, cross-species transmission, or zoonotic potential applies.

## 15. Model organisms and experimental systems

### Available/related models

No well-characterized **Smad2 knock-in model reproducing a specific human LDS6 allele** was found in the retrieved literature. Because complete Smad2 loss has major developmental consequences, constitutive knockout models may poorly represent viable heterozygous human LDS6 and conditional or allele-specific models are preferable.

A highly informative **Tgfbr1-M318R/+ LDS mouse** develops aortic-root dilation and demonstrates lineage-specific pathogenesis: second-heart-field-derived VSMCs show deficient TGF-β-induced pSmad2/3 and target-gene activation, while later diseased tissue exhibits localized excess pSmad2/3 and TGF-β ligand. This recapitulates LDS pathway biology but is **not a SMAD2/LDS6 model**. (macfarlane2019lineagespecificeventsunderlie pages 2-5)

### Cellular models

- Patient fibroblasts and induced myofibroblasts.
- iPSC-derived vascular smooth-muscle cells.
- iPSC-derived endothelial cells.
- Isogenic CRISPR-corrected or knock-in pairs.
- Aortic organoids/tissue-engineered vessels.

A 2024 LDS iPSC-endothelial methodology project highlights these systems as alternatives to rodent models with limited clinical transferability. Applications include variant functional classification, cell-lineage studies, extracellular-matrix and mechanotransduction assays, and drug screening. (ebeling2024differentiationpurificationand pages 9-11)

### Model limitations

Models must reproduce heterozygosity, relevant SMAD2 isoform/domain effects, human arterial-cell lineage, pulsatile mechanical loading, and long disease latency. TGFBR1/TGFBR2/SMAD3 or Marfan models illuminate shared pathways but cannot establish an LDS6-specific phenotype or treatment response.

## Recent developments, authoritative interpretation, and key gaps

Recent 2023–2024 work emphasizes three developments: expanding gene-informed HTAD diagnosis, increasingly comprehensive CT/CMR surveillance, and cell/lineage-specific modeling rather than treating TGF-β signaling as uniformly increased or decreased. MRI/CMR is particularly valuable for repeated imaging because it avoids ionizing radiation and supports biomechanical measurements; next-generation sequencing enables cascade diagnosis across genetically heterogeneous aortopathies. (asta2023geneticbasisnew pages 5-8, spaziani2024hereditarythoracicaortic pages 7-9)

The most important expert-level conclusion is that **SMAD2 is credibly associated with Loeys–Dietz-spectrum aortopathy, but LDS6 remains too sparsely described for independent evidence-based thresholds or outcome estimates**. Open Targets supports the gene–disease association, yet current surveillance and treatment are necessarily extrapolated from broader LDS/HTAD practice. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2)

Priority research needs are: an international SMAD2 registry; standardized variant and domain annotation; age-specific penetrance and phenotype frequencies; whole-arterial natural history; pregnancy outcomes; patient-derived VSMC/endothelial and allele-specific animal models; validated circulating/imaging biomarkers; and genotype-specific treatment and surgical-threshold studies.

## Selected dated sources and URLs

1. Asta L, et al. **Genetic Basis, New Diagnostic Approaches, and Updated Therapeutic Strategies of the Syndromic Aortic Diseases.** Published August 2023. DOI/URL: https://doi.org/10.3390/ijerph20166615. (asta2023geneticbasisnew pages 5-8, asta2023geneticbasisnew pages 3-5)
2. Spaziani G, et al. **Hereditary Thoracic Aortic Diseases.** Published January 2024. DOI/URL: https://doi.org/10.3390/diagnostics14010112. (spaziani2024hereditarythoracicaortic pages 7-9, spaziani2024hereditarythoracicaortic pages 9-10)
3. Ganizada BH, et al. **Unveiling cellular and molecular aspects of ascending thoracic aortic aneurysms and dissections.** Published May 2024. DOI/URL: https://doi.org/10.1007/s00395-024-01053-1. (ganizada2024unveilingcellularand pages 14-15)
4. MacFarlane EG, et al. **Lineage-specific events underlie aortic root aneurysm pathogenesis in Loeys-Dietz syndrome.** Published January 2019. DOI/URL: https://doi.org/10.1172/JCI123547. (macfarlane2019lineagespecificeventsunderlie pages 2-5)
5. Zaza P, et al. **Cleft Palate and Aortic Dilatation as Clues for Loeys–Dietz Syndrome.** Published August 2022. DOI/URL: https://doi.org/10.3390/children9091290. (zaza2022cleftpalateand pages 2-5)
6. ClinicalTrials.gov **NCT05472519, Immunopathology of Loeys-Dietz Syndrome**, completed June 7, 2023: https://clinicaltrials.gov/study/NCT05472519. (NCT05472519 chunk 1)
7. ClinicalTrials.gov **NCT01322165, GenTAC Registry**, completed September 2016: https://clinicaltrials.gov/study/NCT01322165. (NCT01322165 chunk 1)

**Abstract/direct-text support:** The clearest retrieved subtype statement is: “Type 6 shows mutations in SMAD2,” accompanied by the caution that “LDS type 6 is not consistently used in literature.” (ebeling2024differentiationpurificationand pages 9-11) The I-LoDiS trial record characterizes LDS as a “rare vascular genetic disorder” and describes the broader hypothesis of intracellular TGF-β pathway hyperactivation measured by pSMAD2/3; because that study enrolled receptor-positive LDS, this quote is mechanistically relevant but not direct LDS6 evidence. (NCT05472519 chunk 1)

References

1. (asta2023geneticbasisnew pages 3-5): Laura Asta, Gianluca A. D’Angelo, Daniele Marinelli, and Umberto Benedetto. Genetic basis, new diagnostic approaches, and updated therapeutic strategies of the syndromic aortic diseases: marfan, loeys–dietz, and vascular ehlers–danlos syndrome. International Journal of Environmental Research and Public Health, 20:6615, Aug 2023. URL: https://doi.org/10.3390/ijerph20166615, doi:10.3390/ijerph20166615. This article has 40 citations.

2. (ebeling2024differentiationpurificationand pages 9-11): Differentiation, purification, and characterisation of patient iPSC-derived endothelial cells for Loeys-Dietz-Syndrome disease modelling This article has 1 citations and is from a peer-reviewed journal.

3. (OpenTargets Search: Loeys-Dietz syndrome-SMAD2): Open Targets Query (Loeys-Dietz syndrome-SMAD2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

4. (zaza2022cleftpalateand pages 2-5): Pierluigi Zaza, Flavia Indrio, Annalisa Fracchiolla, Matteo Rinaldi, Giovanni Meliota, Alessia Salatto, Antonio Bonacaro, and Gianfranco Maffei. Cleft palate and aortic dilatation as clues for loeys–dietz syndrome. Children, 9:1290, Aug 2022. URL: https://doi.org/10.3390/children9091290, doi:10.3390/children9091290. This article has 2 citations.

5. (liu2025anoveltgfbr2 pages 7-8): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations.

6. (macfarlane2019lineagespecificeventsunderlie pages 2-5): Elena Gallo MacFarlane, Sarah J. Parker, Joseph Y. Shin, Shira G. Ziegler, Tyler J. Creamer, Rustam Bagirzadeh, Djahida Bedja, Yichun Chen, Juan F. Calderon, Katherine Weissler, Pamela A. Frischmeyer-Guerrerio, Mark E. Lindsay, Jennifer P. Habashi, and Harry C. Dietz. Lineage-specific events underlie aortic root aneurysm pathogenesis in loeys-dietz syndrome. Journal of Clinical Investigation, 129:659-675, Jan 2019. URL: https://doi.org/10.1172/jci123547, doi:10.1172/jci123547. This article has 142 citations and is from a highest quality peer-reviewed journal.

7. (NCT05472519 chunk 1):  Immunopathology of Loeys-Dietz Syndrome. Hospices Civils de Lyon. 2022. ClinicalTrials.gov Identifier: NCT05472519

8. (ganizada2024unveilingcellularand pages 14-15): Berta H. Ganizada, Rogier J. A. Veltrop, Asim C. Akbulut, Rory R. Koenen, Ryan Accord, Roberto Lorusso, Jos G. Maessen, Koen Reesink, Elham Bidar, and Leon J. Schurgers. Unveiling cellular and molecular aspects of ascending thoracic aortic aneurysms and dissections. Basic Research in Cardiology, 119:371-395, May 2024. URL: https://doi.org/10.1007/s00395-024-01053-1, doi:10.1007/s00395-024-01053-1. This article has 63 citations and is from a domain leading peer-reviewed journal.

9. (spaziani2024hereditarythoracicaortic pages 7-9): Gaia Spaziani, Francesca Chiara Surace, Francesca Girolami, Francesco Bianco, Valentina Bucciarelli, Francesca Bonanni, Elena Bennati, Luigi Arcieri, and Silvia Favilli. Hereditary thoracic aortic diseases. Diagnostics, 14:112, Jan 2024. URL: https://doi.org/10.3390/diagnostics14010112, doi:10.3390/diagnostics14010112. This article has 7 citations.

10. (asta2023geneticbasisnew pages 5-8): Laura Asta, Gianluca A. D’Angelo, Daniele Marinelli, and Umberto Benedetto. Genetic basis, new diagnostic approaches, and updated therapeutic strategies of the syndromic aortic diseases: marfan, loeys–dietz, and vascular ehlers–danlos syndrome. International Journal of Environmental Research and Public Health, 20:6615, Aug 2023. URL: https://doi.org/10.3390/ijerph20166615, doi:10.3390/ijerph20166615. This article has 40 citations.

11. (NCT01322165 chunk 1):  National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions. National Heart, Lung, and Blood Institute (NHLBI). 2007. ClinicalTrials.gov Identifier: NCT01322165

12. (spaziani2024hereditarythoracicaortic pages 9-10): Gaia Spaziani, Francesca Chiara Surace, Francesca Girolami, Francesco Bianco, Valentina Bucciarelli, Francesca Bonanni, Elena Bennati, Luigi Arcieri, and Silvia Favilli. Hereditary thoracic aortic diseases. Diagnostics, 14:112, Jan 2024. URL: https://doi.org/10.3390/diagnostics14010112, doi:10.3390/diagnostics14010112. This article has 7 citations.

## Artifacts

- [Edison artifact artifact-00](Loeys-Dietz_Syndrome_6-deep-research-falcon_artifacts/artifact-00.md)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 7 |
| Resolved | 7 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 7 |
| On topic | 3 |
| Off topic | 0 |

All extracted references resolved successfully.